DOI

In a groundbreaking study published in Neuron, researchers at Johns Hopkins University uncovered how the psychedelic drug DOI (2,5-dimethoxy-4-iodoamphetamine) reduces anxiety by activating particular neurons in the brain. The research looks at a specific type of brain cell called parvalbumin-...

The Drug Enforcement Administration (DEA) has announced a 10-day hearing to deliberate on the potential ban of two psychedelic compounds, 2,5-dimethoxy-4-iodoamphetamine (DOI) and 2,5-dimethoxy-4-chloroamphetamine (DOC). As reported by Green Market Report, the hearing, scheduled to run from...